Protect the healthy cells, expose the cancer
We aim to cure blood cancers through cell and genome engineering
Vor Bio is developing a proprietary platform built on Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T Cells.
We aren’t inventing new technologies. We’re applying the latest scientific advancements to fight AML in a new way.
Our proprietary platform combines genome engineering, Hematopoietic Stem Cell (HSC) biology, and CAR-T cells to solve urgent unmet medical needs for patients with blood cancers.
We aim to transform treatment by protecting the healthy blood cells and only attacking the cancer cells with targeted therapies post-transplant.
We are currently conducting a clinical trial to further investigate our promising approach.
Our approach genetically edits HSCs from a healthy matched donor to be resistant to targeted therapies in the patient post-transplant.
By protecting healthy cells, we are aiming to delay or prevent relapse and enable cures for patients with AML and other blood cancers.
Our Phase 1/2a clinical trial is actively recruiting patients.
Come be a part of a team that is developing a unique approach to one of medicine’s greatest challenges—eradicating cancer.